|
|
Post by InvesterSam on Aug 13, 2017 15:36:46 GMT -5
It seems a case study published by Harvard Business School? Does anyone have access to the contents? www.hbs.edu/faculty/Pages/item.aspx?num=53095 CASE | HBS CASE COLLECTION | AUGUST 2017 MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work by Elie Ofek and Amanda Dai Abstract In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to injectable rapid-acting (or mealtime) insulin, Afrezza boasted a potential market of at least 4 million diabetic patients. Shortly thereafter, Sanofi, a company with vast experience in the diabetic space, became MannKind’s marketing partner and helped launch Afrezza in February, 2015. Although the drug had a black box warning and required doctors to perform a lung test on patients, expectations were high, with some analysts predicting peak sales of up to $4 billion a year. However, those lofty hopes were quickly dashed when Afrezza generated lackluster first-year sales, driving Sanofi to terminate its short-lived contract with MannKind in January, 2016. MannKind’s management attributed the launch’s failure to a poor marketing approach, convinced that Sanofi, despite its strong global presence and experience, did not effectively address critical barriers to adoption. The company now planned to overhaul Afrezza’s entire marketing strategy. This included rethinking: which patients and physicians to target, how to position the drug to engender interest and adoption, how to lower end consumer price, through which media to convey Afrezza’s benefits, and how to streamline the process of performing the lung-test and getting the drug into the hands of patients. But would all these changes and initiatives, no matter how well executed, be enough to turn sales around? Would Afrezza ever realize the potential that Alfred Mann, the late founder and former CEO, saw in the novel treatment? Language: English Format: Print 27 pages |
|
|
|
Post by tarheelblue004 on Aug 13, 2017 16:00:07 GMT -5
Awesome! Would LOVE to get my hands on this...
|
|
|
|
Post by peppy on Aug 13, 2017 16:07:03 GMT -5
Was Harvard one of the beneficiaries of Al Mann's will?
|
|
|
|
Post by mnkdorbust on Aug 13, 2017 16:38:02 GMT -5
Harvard Business School Case 518-031
Tried as well to get access to it with no luck.
|
|
|
|
Post by mango on Aug 13, 2017 17:23:08 GMT -5
This is a marketing piece, not a scientific publication. However, it could be interesting nonetheless. Email sent to the author already about full text access.
The only relation to Alfred Mann with this is the Primary author, Elie Ofek, received an Electrical Engineering degree from the Technion. He also received an MA in economics and a PhD in Business (both from Stanford). He is a marketing professor at HBS and writes reports on pharma related things.
The co-author (I am half joking here and half not) is, Amanda Dai, and this person appears to be either: a high school senior, a talent agent, an Olympic skater, an interpreter, or a student (or perhaps none of the above).
|
|
|
|
Post by mango on Aug 13, 2017 17:56:09 GMT -5
Called the Harvard Business Review and the woman I spoke with said the faculty member normally requests for their cases to be made available via Harvard Business Publishing and she did multiple searches and did not find a currently available full text. It probably was just finished and the author hasn't had a chance to do that. Will call the Professor tomorrow. I did get clarity on what this is though. This is a Case write up for teaching purposes. Since the author has the Technion connection I imagine this is a meaningful coincidence, so will hopefully be able to find out more tomorrow. Nice find InvesterSam |
|
|
|
Post by factspls88 on Aug 14, 2017 8:51:39 GMT -5
As an alum I can confirm this is a case study for teaching purposes. The write up will not express a point of view but rather lay out the situation Mannkind has faced and is facing as a starting point of discussion. There is often, but not always, some accompanying data. In the class students will assess the situation and offer a set of conclusions based on the information provided in the case as well as other info they may have. Importantly, there is often no right or wrong answer (just as is often the case in business) and students will often disagree on their assessment of the situation. PS I have no special access to the case materials.
|
|
|
|
Post by joeypotsandpans on Aug 14, 2017 11:25:43 GMT -5
As an alum I can confirm this is a case study for teaching purposes. The write up will not express a point of view but rather lay out the situation Mannkind has faced and is facing as a starting point of discussion. There is often, but not always, some accompanying data. In the class students will assess the situation and offer a set of conclusions based on the information provided in the case as well as other info they may have. Importantly, there is often no right or wrong answer (just as is often the case in business) and students will often disagree on their assessment of the situation. PS I have no special access to the case materials. Ironically, it was two alum that helped cause this mess, BO and the person he appointed MH both of which are fortunately miles away from the FDA these days. Having said that, as far as the case study, bunch of smart individuals and some with $$$. Most likely will end up with some taking additional shares out of inventory of the borrowed and lent pool, have no issues with that  , rolling over and going back to sleep, nice to see some familiar faces albeit a few years older lol. It's been a while since I have added to my inventory but over the last two weeks have taken some serious bites both shares and options. Ok, once again wake me up when it's over....oh yeah btw, sleeping better with the new mgmt. team Zzzzzzzz. -J |
|
|
|
Post by liane on Aug 14, 2017 11:34:02 GMT -5
Good to hear from you joey; hope your slumber does not need to be too long.
|
|
|
|
Post by factspls88 on Aug 14, 2017 12:48:07 GMT -5
As an alum I can confirm this is a case study for teaching purposes. The write up will not express a point of view but rather lay out the situation Mannkind has faced and is facing as a starting point of discussion. There is often, but not always, some accompanying data. In the class students will assess the situation and offer a set of conclusions based on the information provided in the case as well as other info they may have. Importantly, there is often no right or wrong answer (just as is often the case in business) and students will often disagree on their assessment of the situation. PS I have no special access to the case materials. Ironically, it was two alum that helped cause this mess, BO and the person he appointed MH both of which are fortunately miles away from the FDA these days. Having said that, as far as the case study, bunch of smart individuals and some with $$$. Most likely will end up with some taking additional shares out of inventory of the borrowed and lent pool, have no issues with that , rolling over and going back to sleep, nice to see some familiar faces albeit a few years older lol. It's been a while since I have added to my inventory but over the last two weeks have taken some serious bites both shares and options. Ok, once again wake me up when it's over....oh yeah btw, sleeping better with the new mgmt. team Zzzzzzzz. -J BO went to Harvard Law, not B-School. Hamburg went to Med school. That said, plenty of winners and losers from b-school. |
|
|
|
Post by joeypotsandpans on Aug 14, 2017 13:24:04 GMT -5
Good to hear from you joey; hope your slumber does not need to be too long. Can't agree. Political attacks should be banned from this board, whether they be directed at Trump or Obama. Let's be clear, the attack if you want to call it that was specifically on the individuals and not their political affiliation, lets not get defensive now and make any unnecessary assumptions as you are the one making it political in your mind .....mine was more a statement of how the trials were set up to fail via an inept FDA appointed individual that had a severe and blatant conflict of interest. This has been hashed over in some historical posts here and on the old Yahoo message boards if you wish to grab a bag of popcorn and do some due diligence. I could care less what party they were affiliated with, the damage that was done and lives impaired by her actions or lack of proper action and the individual responsible for putting her in that position are IMO directly responsible for making Al go through some undue hell in his efforts to get this to market in a more timely and far less expensive fashion. I stated two facts, the first being they were alumni and associated with the overall same institution as alumni of Harvard (as facts pointed out separate affiliated branches of same) the other being that a big part of the mess that was created financially was due to the time and costs of the company having to go through the two trials and having to finally get it in front of an unbiased ADCOM panel (other than the individual from NOVO). C'mon Lefty you should know better, this was totally MNKD related and far from a jab at the specific party they were affiliated with. Bringing this back to topic, I appreciate Investor Sam posting the thread as the individual behind the case study discussion has a tremendous resume and I would love to hear and be part of the discussion among the students and their thoughts -J |
|
|
|
Post by kball on Aug 14, 2017 13:44:02 GMT -5
Sorry Pots.
In retrospect, that was the easy part
|
|
|
|
Post by porkini on Aug 14, 2017 13:49:52 GMT -5
Can't agree. Political attacks should be banned from this board, whether they be directed at Trump or Obama. Let's be clear, the attack if you want to call it that was specifically on the individuals and not their political affiliation, lets not get defensive now and make any unnecessary assumptions as you are the one making it political in your mind .....mine was more a statement of how the trials were set up to fail via an inept FDA appointed individual that had a severe and blatant conflict of interest. This has been hashed over in some historical posts here and on the old Yahoo message boards if you wish to grab a bag of popcorn and do some due diligence. I could care less what party they were affiliated with, the damage that was done and lives impaired by her actions or lack of proper action and the individual responsible for putting her in that position are IMO directly responsible for making Al go through some undue hell in his efforts to get this to market in a more timely and far less expensive fashion. I stated two facts, the first being they were alumni and associated with the overall same institution as alumni of Harvard (as facts pointed out separate affiliated branches of same) the other being that a big part of the mess that was created financially was due to the time and costs of the company having to go through the two trials and having to finally get it in front of an unbiased ADCOM panel (other than the individual from NOVO). C'mon Lefty you should know better, this was totally MNKD related and far from a jab at the specific party they were affiliated with. Bringing this back to topic, I appreciate Investor Sam posting the thread as the individual behind the case study discussion has a tremendous resume and I would love to hear and be part of the discussion among the students and their thoughts -J Sorry, but I fail to see what this has to do with "Harvard Business School Case Study?" Sounds more like someone's corn flakes got whizzed in.  |
|
|
|
Post by babaoriley on Aug 14, 2017 15:17:09 GMT -5
Can't agree. Political attacks should be banned from this board, whether they be directed at Trump or Obama. Let's be clear, the attack if you want to call it that was specifically on the individuals and not their political affiliation, lets not get defensive now and make any unnecessary assumptions as you are the one making it political in your mind .....mine was more a statement of how the trials were set up to fail via an inept FDA appointed individual that had a severe and blatant conflict of interest. This has been hashed over in some historical posts here and on the old Yahoo message boards if you wish to grab a bag of popcorn and do some due diligence. I could care less what party they were affiliated with, the damage that was done and lives impaired by her actions or lack of proper action and the individual responsible for putting her in that position are IMO directly responsible for making Al go through some undue hell in his efforts to get this to market in a more timely and far less expensive fashion. I stated two facts, the first being they were alumni and associated with the overall same institution as alumni of Harvard (as facts pointed out separate affiliated branches of same) the other being that a big part of the mess that was created financially was due to the time and costs of the company having to go through the two trials and having to finally get it in front of an unbiased ADCOM panel (other than the individual from NOVO). C'mon Lefty you should know better, this was totally MNKD related and far from a jab at the specific party they were affiliated with. Bringing this back to topic, I appreciate Investor Sam posting the thread as the individual behind the case study discussion has a tremendous resume and I would love to hear and be part of the discussion among the students and their thoughts -J "I appreciate Investor Sam posting the thread as the individual behind the case study discussion has a tremendous resume and I would love to hear and be part of the discussion among the students and their thoughts." That would be interesting, wouldn't it? I have a feeling they got most of their ideas from researching this board! Good to see your handle back on here, Joey! You need to watch over our buddy, Glenn - he needs lots of watching! |
|
|
|
Post by mango on Aug 14, 2017 16:50:03 GMT -5
Received an email response today from someone on behalf of the Professor. • I can see the Professor having to change his curriculum for the remainder of the year if his students were to stumble upon this website in preparation for their discussions. The story is just far too complex and filled with mystery, and the kicker would be the connection the Professor has with Al Mann—Technion. factspls88 correct me if I am wrong, but I believe the HBS makes some of their case studies that involve student discussion accessible on the website. I came across a page that was just for that and related things but didn't click on any of the cases to see if it was public access or required a student or faculty login. I'd love to see some highly educated and unbiased discussion by people that probably had very little knowledge of MannKind and Afrezza prior to this case study. |
|
, rolling over and going back to sleep, nice to see some familiar faces albeit a few years older lol. It's been a while since I have added to my inventory but over the last two weeks have taken some serious bites both shares and options. Ok, once again wake me up when it's over....oh yeah btw, sleeping better with the new mgmt. team Zzzzzzzz. -J 
